USA Domestic Delivery,Canada Domestic Delivery,European Domestic Delivery

Medrogestone (977-79-7)

Rating:
5.00 out of 5 based on 1 customer rating
SKU: 977-79-7. Category:

AASraw is with synthesis and production ability from gram to mass order of Medrogestone (977-79-7), under CGMP regulation and trackable quality control system.

blank

Product Description

 

Medrogestone (977-79-7) video

 

 


 

Medrogestone (977-79-7) Specification:

Chemical Structure: Product Name: Medrogestone
  Cas No.: 977-79-7
Molecular Formula: C23H32O2
Molecular Weight: 340.5
Synonyms: MEDROGESTONE

977-79-7

Medrogesterone

Metrogestone

Colprone

Storage: Dry, dark
Documents(COA & HPLC etc.): Available

 

Medrogestone (977-79-7) Description:

Medrogestone powder (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective option. that has been used in hormone replacement therapy for menopausal symptoms and in the treatment of gynecological disorders.

And Medrogestone powder, sold under the brand name Colprone among others, is a progestin medication which has been used in menopausal hormone therapy and in the treatment of gynecological disorders. It is available both alone and in combination with an estrogen. It is taken by mouth.

Medrogestone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has weak antiandrogenic, glucocorticoid, and antimineralocorticoid activity and no other important hormonal activity. Due to its progestogenic activity, medrogestone has antigonadotropic effects.

 

Reference:

  • 1: Schindler AE. Dydrogesterone and other progestins in benign breast disease: an overview. Arch Gynecol Obstet. 2011 Feb;283(2):369-71. doi: 10.1007/s00404-010-1456-7. Epub 2010 Apr 11. Review. PubMed PMID: 20383772.
  • 2: Pasqualini JR. Breast cancer and steroid metabolizing enzymes: the role of progestogens. Maturitas. 2009 Dec;65 Suppl 1:S17-21. doi: 10.1016/j.maturitas.2009.11.006. Epub 2009 Dec 3. Review. PubMed PMID: 19962254.
  • 3: Pasqualini JR. Estrogen sulfotransferases in breast and endometrial cancers. Ann N Y Acad Sci. 2009 Feb;1155:88-98. doi: 10.1111/j.1749-6632.2009.04113.x. Review. PubMed PMID: 19250196.
  • 4: Pasqualini JR. Progestins in the menopause in healthy women and breast cancer patients. Maturitas. 2009 Apr 20;62(4):343-8. doi: 10.1016/j.maturitas.2008.12.008. Review. PubMed PMID: 19179024.
  • 5: Pasqualini JR. Progestins and breast cancer. Gynecol Endocrinol. 2007 Oct;23 Suppl 1:32-41. Review. PubMed PMID: 17943537.

 

PRECAUTION AND DISCLAIMER:

This Material is Sold For Research Use Only. Terms of Sale Apply. Not for Human Consumption, nor Medical, Veterinary, or Household Uses.